{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:01:47Z","timestamp":1790215307511,"version":"4.1.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1681\/asn.2010111160","type":"journal-article","created":{"date-parts":[[2011,9,24]],"date-time":"2011-09-24T03:26:32Z","timestamp":1316834792000},"page":"2107-2118","source":"Crossref","is-referenced-by-count":126,"title":["Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney Transplantation"],"prefix":"10.1681","volume":"22","author":[{"given":"Adnan","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Shabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Borrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20230423","first-page":"1867","article-title":"The discovery and development of cyclosporine (Sandimmune)","volume":"23","author":"Borel","year":"1991","journal-title":"Transplant Proc"},{"key":"R2-19-20230423","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"R5-19-20230423","first-page":"2523","article-title":"Cyclosporine in cadaveric renal transplantation: A prospective randomized trial","volume":"15","author":"McMaster","year":"1983","journal-title":"Transplant Proc"},{"key":"R6-19-20230423","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-19-20230423","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jama.1993.03500030093040","article-title":"Elective cyclosporine withdrawal after renal transplantation. A meta-analysis","volume":"269","author":"Kasiske","year":"1993","journal-title":"JAMA"},{"key":"R8-19-20230423","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/TP.0b013e3181949e71","article-title":"Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation","volume":"87","author":"Moore","year":"2009","journal-title":"Transplantation"},{"key":"R9-19-20230423","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"R10-19-20230423","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10157-007-0467-6","article-title":"Prospective randomized study of azathioprine vs. cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience","volume":"11","author":"Gheith","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"R12-19-20230423","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.tp.0000225803.04995.2b","article-title":"Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients","volume":"82","author":"Asberg","year":"2006","journal-title":"Transplantation"},{"key":"R13-19-20230423","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"R14-19-20230423","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients","volume":"9","author":"Busque","year":"2009","journal-title":"Am J Transplant"},{"key":"R15-19-20230423","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A Phase III study of beletacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"R16-19-20230423","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/TP.0b013e318160d3c9","article-title":"Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor","volume":"85","author":"Durrbach","year":"2008","journal-title":"Transplantation"},{"key":"R17-19-20230423","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R18-19-20230423","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"R20-19-20230423","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/01.tp.0000232688.76018.19","article-title":"High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation","volume":"82","author":"Gelens","year":"2006","journal-title":"Transplantation"},{"key":"R21-19-20230423","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"R22-19-20230423","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1600-6143.2005.01064.x","article-title":"Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation","volume":"5","author":"Hamdy","year":"2005","journal-title":"Am J Transplant"},{"key":"R23-19-20230423","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"R24-19-20230423","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"key":"R25-19-20230423","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.tp.0000235823.09788.f6","article-title":"Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center","volume":"82","author":"Martinez-Mier","year":"2006","journal-title":"Transplantation"},{"key":"R26-19-20230423","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000658-198502000-00003","article-title":"A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients","volume":"201","author":"Najarian","year":"1985","journal-title":"Ann Surg"},{"key":"R27-19-20230423","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00007890-198608000-00010","article-title":"Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study","volume":"42","author":"Novick","year":"1986","journal-title":"Transplantation"},{"key":"R28-19-20230423","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"R29-19-20230423","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R30-19-20230423","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181db09e4","article-title":"Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids","volume":"89","author":"Glotz","year":"2010","journal-title":"Transplantation"},{"key":"R31-19-20230423","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation"},{"key":"R33-19-20230423","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1432-2277.2002.tb00106.x","article-title":"Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients","volume":"15","author":"Grimbert","year":"2002","journal-title":"Transpl Int"},{"key":"R34-19-20230423","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198806093182304","article-title":"Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine","volume":"318","author":"Hall","year":"1988","journal-title":"N Engl J Med"},{"key":"R35-19-20230423","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/00007890-198805000-00014","article-title":"A randomized trial comparing triple-drug and double-drug therapy in renal transplantation","volume":"45","author":"Ponticelli","year":"1988","journal-title":"Transplantation"},{"key":"R36-19-20230423","first-page":"309","article-title":"Cadaveric renal transplantation under cyclosporine-steroid therapy","volume":"157","author":"Rosenthal","year":"1983","journal-title":"Surg Gynecol Obstet"},{"key":"R37-19-20230423","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.transproceed.2006.10.098","article-title":"Short-term results under three different immunosuppressive regimens at one center","volume":"38","author":"Schaefer","year":"2006","journal-title":"Transplant Proc"},{"key":"R40-19-20230423","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1681\/ASN.V1281750","article-title":"A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids","volume":"12","author":"de S\u00e9vaux","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R41-19-20230423","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"R42-19-20230423","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients\u2013An interim analysis","volume":"5","author":"Kandaswamy","year":"2005","journal-title":"Am J Transplant"},{"key":"R43-19-20230423","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"R44-19-20230423","doi-asserted-by":"crossref","first-page":"115S","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients","volume":"35","author":"Russ","year":"2003","journal-title":"Transplant Proc"},{"key":"R45-19-20230423","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial","volume":"88","author":"Salvadori","year":"2009","journal-title":"Transplantation"},{"key":"R46-19-20230423","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"R47-19-20230423","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/01.tp.0000282872.17024.b7","article-title":"Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression","volume":"84","author":"Hern\u00e1ndez","year":"2007","journal-title":"Transplantation"},{"key":"R48-19-20230423","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/01.tp.0000251718.95622.b3","article-title":"Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation","volume":"82","author":"Tedesco-Silva","year":"2006","journal-title":"Transplantation"},{"key":"R49-19-20230423","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/TP.0b013e3181ba06ee","article-title":"A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration","volume":"88","author":"Andr\u00e9s","year":"2009","journal-title":"Transplantation"},{"key":"R50-19-20230423","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1399-0012.2008.00891.x","article-title":"A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function","volume":"23","author":"Andr\u00e9s","year":"2009","journal-title":"Clin Transplant"},{"key":"R51-19-20230423","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5414\/CNP67164","article-title":"Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab","volume":"67","author":"Budde","year":"2007","journal-title":"Clin Nephrol"},{"key":"R52-19-20230423","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"R53-19-20230423","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"R54-19-20230423","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","article-title":"FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia","volume":"6","author":"Salvadori","year":"2006","journal-title":"Am J Transplant"},{"key":"R55-19-20230423","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"R56-19-20230423","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0272-6386(97)90487-X","article-title":"A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients","volume":"30","author":"Kasiske","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R57-19-20230423","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"R58-19-20230423","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1600-6143.2006.01291.x","article-title":"Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study","volume":"6","author":"Kamar","year":"2006","journal-title":"Am J Transplant"},{"key":"R59-19-20230423","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"R60-19-20230423","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"R61-19-20230423","first-page":"366","article-title":"Cyclosporin A: Early or delayed onset by prophylactic immunosuppression?","volume":"8","author":"Wienand","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"R62-19-20230423","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients","volume":"20","author":"No\u00ebl","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R63-19-20230423","doi-asserted-by":"crossref","first-page":"SS3","DOI":"10.1097\/01.TP.0000069952.49242.3E","article-title":"New-onset diabetes after transplantation: 2003 International consensus guidelines","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"R64-19-20230423","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"R65-19-20230423","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(05)17962-8","article-title":"New-onset diabetes after transplantation: A threat to graft and patient survival","volume":"365","author":"Krentz","year":"2005","journal-title":"Lancet"},{"key":"R66-19-20230423","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomized trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"R67-19-20230423","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis","volume":"4","author":"Heisel","year":"1994","journal-title":"Am J Transplant"},{"key":"R68-19-20230423","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1600-6143.2010.03104.x","article-title":"The elephant in the room: Failings of current clinical endpoints in kidney transplantation","volume":"10","author":"Schold","year":"2010","journal-title":"Am J Transplant"},{"key":"R69-19-20230423","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1681\/ASN.2005080891","article-title":"Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies","volume":"17","author":"Roos-van Groningen","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R70-19-20230423","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1681\/ASN.2005030249","article-title":"No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year","volume":"17","author":"Rowshani","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R71-19-20230423","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1097\/01.ASN.0000095250.92361.D5","article-title":"Long-term graft survival with neoral and tacrolimus: A paired kidney analysis","volume":"14","author":"Kaplan","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R72-19-20230423","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/TP.0b013e31818046db","article-title":"Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots","volume":"86","author":"Augustine","year":"2008","journal-title":"Transplantation"},{"key":"R73-19-20230423","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-128-10-199805150-00004","article-title":"The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group","volume":"128","author":"Szczech","year":"1998","journal-title":"Ann Intern Med"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201111000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:21:00Z","timestamp":1786130460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201111000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2010111160","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}